[{"id":"d5870014-be37-4a8f-b38f-acf430db9ed2","acronym":"TIBIOP-LMC","url":"https://clinicaltrials.gov/study/NCT04645706","created_at":"2021-01-19T20:39:33.885Z","updated_at":"2024-07-02T16:35:40.883Z","phase":"","brief_title":"Innate T Cells and TKI Discontinuation","source_id_and_acronym":"NCT04645706 - TIBIOP-LMC","lead_sponsor":"Poitiers University Hospital","biomarkers":" CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20","pipe":" | ","alterations":" CD8 expression • IFNG expression","tags":["CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-04"},{"id":"26302c51-826a-4bcf-a643-430566444730","acronym":"","url":"https://clinicaltrials.gov/study/NCT05371392","created_at":"2022-05-12T15:56:35.878Z","updated_at":"2024-07-02T16:36:10.571Z","phase":"","brief_title":"ITGA4 Gene Methylation Status in Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05371392","lead_sponsor":"Sohag University","biomarkers":" ITGA4","pipe":"","alterations":" ","tags":["ITGA4"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2022-05-12"},{"id":"6e11b1bd-5499-4695-84ba-d75b5547d6f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03380299","created_at":"2021-01-18T16:40:52.767Z","updated_at":"2024-07-02T16:37:15.380Z","phase":"","brief_title":"Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis","source_id_and_acronym":"NCT03380299","lead_sponsor":"Assiut University","biomarkers":" CD44 • ITGA4","pipe":"","alterations":" ","tags":["CD44 • ITGA4"],"overall_status":"Unknown status","enrollment":" Enrollment 2","initiation":"Initiation: 07/14/2016","start_date":" 07/14/2016","primary_txt":" Primary completion: 09/14/2018","primary_completion_date":" 09/14/2018","study_txt":" Completion: 12/14/2018","study_completion_date":" 12/14/2018","last_update_posted":"2017-12-21"},{"id":"702a7bee-1abe-4383-a05e-f3c42e8ae277","acronym":"","url":"https://clinicaltrials.gov/study/NCT01369849","created_at":"2021-01-18T05:36:41.184Z","updated_at":"2024-07-02T16:37:17.871Z","phase":"Phase 1/2","brief_title":"Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT01369849","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • IGH • CD38 • CD5 • ITGA4 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • IGH • CD38 • CD5 • ITGA4 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • MK-2206 • bendamustine • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2017-09-15"}]